Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer

NCT07019337 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer
Metastatic Breast Cancer

Interventions

DRUG: Pyrotinib
DRUG: Capecitabine

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences